Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic?

JCO Oncol Pract. 2021 Jul;17(7):455-456. doi: 10.1200/OP.20.01091. Epub 2021 Apr 2.

Authors

Yakup Ergun¹, Selin Akturk Esen¹, Gokhan Ucar¹, Yusuf Acikgoz¹, Cengiz Karacin¹

Affiliation

¹ Yakup Ergun, MD, Medical Oncology Unit, Batman Training and Research Hospital, Batman, Turkey; Selin Akturk Esen, MD, Gokhan Ucar, MD, Yusuf Acikgoz, MD, Medical Oncology Unit, Ankara City Hospital, Ankara, Turkey; and Cengiz Karacin, MD, Medical Oncology Unit, RTE Training and Research Hospital, Rize, Turkey.

PMID: 33797950
DOI: 10.1200/OP.20.01091

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Febrile Neutropenia* / drug therapy
Febrile Neutropenia* / epidemiology
Febrile Neutropenia* / prevention & control
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Pandemics
SARS-CoV-2

Substances

Granulocyte Colony-Stimulating Factor